Sign in →

Test Code BA190 BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies

Reporting Name

BCR/ABL1, p190, Quant, Monitor

Useful For

Monitoring response to therapy in patients with known e1/a2 BCR/ABL1 (p190) fusion forms

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type


Advisory Information

This test should not be used to screen for BCR/ABL1 fusions at the time of diagnosis; order either BADX / BCR/ABL1, Qualitative, Diagnostic Assay, Varies; or BCRFX / BCR/ABL1 Qualitative Diagnostic Assay with Reflex to BCR/ABL1 p190 Quantitative Assay or BCR/ABL1 p210 Quantitative Assay, Varies should be ordered for that purpose.


To monitor patients carrying BCR/ABL1 fusion forms coding for the p210 protein, which includes most patients with chronic myeloid leukemia (CML); order BCRAB / BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies.

Shipping Instructions

Refrigerate specimens must arrive within 5 days (120 hours) of collection, and ambient specimens must arrive within 3 days (72 hours) of collection. Collect and package specimen as close to shipping time as possible.

Necessary Information

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR/ABL1-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Specimen Required

Submit only 1 of the following specimens:



Specimen Type: Whole blood


Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 10 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send specimen in original tube.

3. Label specimen as blood.


Specimen Type: Bone marrow


Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 4 mL

Collection Instructions:

1. Invert several times to mix bone marrow.

2. Send specimen in original tube.

3. Label specimen as bone marrow.

Specimen Minimum Volume

Blood: 4 mL
Bone marrow: 2 mL

Specimen Stability Information

Specimen Type Temperature Time
Varies Refrigerated (preferred) 5 days
  Ambient  72 hours

Reference Values

The presence or absence of the BCR/ABL1 mRNA fusion form producing the p190 fusion protein is reported. If positive, the level is reported as the ratio of BCR/ABL1 (p190) transcript to ABL1 transcript in the form of a percentage.

Day(s) and Time(s) Performed

Monday through Saturday; a.m.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

81207-BCR/ABL1 (t[9;22]) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BA190 BCR/ABL1, p190, Quant, Monitor In Process


Result ID Test Result Name Result LOINC Value
39470 BCR/ABL1 p190 Result No LOINC Needed
MP002 Specimen Type 31208-2
19765 Interpretation 69047-9

Clinical Information

mRNA transcribed from BCR/ABL1 (fusion of the breakpoint cluster region gene [BCR] at chromosome 22q11 to the Abelson gene [ABL1] at chromosome 9q34) is detected in all patients with chronic myeloid leukemia (CML) and a subset of patients with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Although breakpoints in the BCR and ABL1 genes may occur in a variety of locations, splicing of the primary RNA transcripts result in only 8 fusion site variants (e1/a2, e6/a2, e13/a2, e14/a2, e19/a2, and e1/a3, e13/a3, e14/a3), which incorporate the entire sequence of the exons on both sides of the fusion site. The e1/a2 and e1/a3 fusion forms produce a 190-kDa protein designated p190. This BCR/ABL1 protein form is found in approximately 75% of patients with childhood ALL and approximately 50% of patients with adult ALL, with the majority arising from e1/a2 mRNA. The p190 is also the predominant fusion form in a small subset of patients with CML, although the vast majority of CML cases contain the p210 protein, typically from e13/a2 or e14/a2 mRNA fusions. Other fusion forms are very rare.


Quantitative reverse-transcription PCR (qRT-PCR) is the most sensitive method for monitoring BCR/ABL1 levels during treatment. This test detects mRNA coding for the most common p190 fusion form (e1/a2).

Analytic Time

4 days

Reject Due To


Mild OK; Gross reject






Moderately to severely clotted

NY State Approved


Method Name

Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)


1. Hematopathology Patient Information (T676) in Special Instructions

2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.

Testing Algorithm

See BCR/ABL1 Ordering Guide for Blood and Bone Marrow in Special Instructions.